BRIDGEBIO PHARMA INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Eric Aguiar, M.D.

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Eric Aguiar, M.D.”): 139,080,658 for, 4,552,096 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 37,265,885 for, 2,412,317 withheld, 303,991 abstained.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Ali J. Satvat

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Ali J. Satvat”): 106,237,448 for, 37,395,306 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 23,958,343 for, 144 against, 14,662,680 withheld, 781,612 abstained.

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Andrea J. Ellis

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Andrea J. Ellis”): 139,229,888 for, 4,402,866 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 36,686,471 for, 2,412,317 withheld, 303,991 abstained.

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Fred Hassan

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Fred Hassan”): 137,076,192 for, 6,556,562 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 36,286,126 for, 2,794,216 withheld, 322,437 abstained.

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Jennifer E. Cook

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Jennifer E. Cook”): 139,063,404 for, 4,569,350 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 36,686,471 for, 2,412,317 withheld, 303,991 abstained.

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

Description as filed by funds: To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 6,500,000 shares.

BRIDGEBIO PHARMA INC.’s own tally for this item (“4. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan”): 118,318,376 for, 25,003,526 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 - Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan The Company's stockholders approved the amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (th…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 92 asset managers below reported 32,696,409 for, 7,440,301 against, 23,210 abstained.

Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.

Description as filed by funds: To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.

BRIDGEBIO PHARMA INC.’s own tally for this item (“2. Non-binding Advisory Vote on Compensation of Named Executive Officers”): 134,309,832 for, 9,254,636 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 89 managers: 35,190,420 for, 4,770,093 against, 23,210 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 221 managers: 107,774,649 for, 8,041,434 against, 18 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.

BRIDGEBIO PHARMA INC.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Accounting Firm”): 160,661,642 for, 196,629 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 39,960,453 for, 23,210 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.